Nicholas Company Inc. lessened its stake in Icon Plc (NASDAQ:ICLR) by 1.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 54,025 shares of the medical research company’s stock after selling 930 shares during the period. Nicholas Company Inc.’s holdings in Icon were worth $6,980,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its stake in Icon by 10.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 164,947 shares of the medical research company’s stock worth $21,860,000 after buying an additional 15,137 shares during the last quarter. US Bancorp DE grew its stake in Icon by 18.6% during the 3rd quarter. US Bancorp DE now owns 3,650 shares of the medical research company’s stock worth $561,000 after buying an additional 573 shares during the last quarter. LSV Asset Management purchased a new position in Icon during the 3rd quarter worth approximately $1,462,000. Prudential Financial Inc. purchased a new position in Icon during the 3rd quarter worth approximately $200,000. Finally, MML Investors Services LLC grew its stake in Icon by 47.1% during the 3rd quarter. MML Investors Services LLC now owns 13,935 shares of the medical research company’s stock worth $2,143,000 after buying an additional 4,465 shares during the last quarter. Institutional investors and hedge funds own 86.41% of the company’s stock.
Icon stock opened at $134.64 on Friday. Icon Plc has a twelve month low of $110.21 and a twelve month high of $155.33. The company has a quick ratio of 2.18, a current ratio of 2.18 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.11 billion, a price-to-earnings ratio of 21.41, a P/E/G ratio of 1.65 and a beta of 0.66.
A number of research analysts recently issued reports on ICLR shares. Mizuho upgraded Icon from a “neutral” rating to a “buy” rating and raised their price target for the stock from $146.00 to $150.00 in a research note on Friday, January 25th. Goldman Sachs Group downgraded Icon from a “conviction-buy” rating to a “buy” rating and set a $168.00 price target on the stock. in a research note on Friday, December 14th. BidaskClub downgraded Icon from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 5th. SunTrust Banks reaffirmed a “buy” rating and set a $161.00 price objective on shares of Icon in a research report on Monday, February 25th. Finally, Barclays increased their price objective on Icon from $130.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 21st. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $152.60.
Icon Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: Back-End Load
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.